Myriad Genetics Inc (MYGN)
Official siteHEALTHCARE • DIAGNOSTICS & RESEARCH • NASDAQ
Market Cap: $542.92M
Last updated: Nov 17, 2026 at 11:06 AM ET
Myriad Genetics Inc (MYGN) Stock Forecast
Analysts expect Myriad Genetics (MYGN) to earn -$0.71 per share in the fiscal year ending Dec 31, 2026, on revenue of $785.10M. Of 9 analysts, 1 rates the stock Buy or Strong Buy, 6 Hold and 2 Sell or Strong Sell, for a consensus of Hold. For the fiscal year ending Dec 31, 2027, the EPS consensus is -$0.60.
Analyst Ratings
Scoring Strong Buy as 1 and Strong Sell as 5, the 9 ratings average 3.22, inside the Hold band from 2.5 up to 3.5. Sell and Strong Sell make up 22% of the ratings.
| Rating | Analysts | Share |
|---|---|---|
| Strong Buy | 0 | 0.0% |
| Buy | 1 | 11.1% |
| Hold | 6 | 66.7% |
| Sell | 1 | 11.1% |
| Strong Sell | 1 | 11.1% |
- Consensus
- Hold
- Total analysts
- 9
Price Target
Analyst price targets are part of paid GNG plans. See plans
Annual Estimates
From the first fiscal year below to the second, the EPS consensus shows a smaller loss and revenue estimates fall 6.0%.
- Fiscal year ending Dec 31, 2026
- -$0.71
- EPS consensus, revenue $785.10M
- Fiscal year ending Dec 31, 2027
- -$0.60
- EPS consensus, revenue $737.70M
- Next report
- Feb 22, 2027
- Estimated
EPS range
Revenue range
| Fiscal year ending | EPS consensus | EPS range | EPS analysts | Revenue consensus | Revenue range | Rev. analysts |
|---|---|---|---|---|---|---|
| Dec 31, 2026 | -$0.71 | -$0.85 to -$0.66 | 6 | $785.10M | $778.40M to $787.90M | 7 |
| Dec 31, 2027 | -$0.60 | -$1.24 to -$0.28 | 7 | $737.70M | $651.90M to $820.23M | 8 |
Quarterly Estimates
The EPS consensus rises from -$0.24 for the quarter ending Dec 31, 2026 to -$0.17 for the quarter ending Mar 31, 2027.
EPS range
Revenue range
| Quarter ending | EPS consensus | EPS range | EPS analysts | Revenue consensus | Revenue range | Rev. analysts |
|---|---|---|---|---|---|---|
| Dec 31, 2026 | -$0.24 | -$0.32 to -$0.17 | 11 | $196.10M | $187.03M to $203.81M | 11 |
| Mar 31, 2027 | -$0.17 | -$0.31 to -$0.08 | 5 | $190.28M | $160.40M to $206.40M | 6 |
Estimate Revisions
Across the 2 periods below, the last 30 days brought 2 upward and 5 downward EPS revisions.
| Period | Up 30 days | Down 30 days |
|---|---|---|
| Fiscal year ending Dec 31, 2027 | 2 | 1 |
| Quarter ending Mar 31, 2027 | 0 | 4 |
EPS Trend
Over the last 90 days, the EPS consensus for the fiscal year ending Dec 31, 2026 has worsened from -$0.70.
| Period | Now | 7 days ago | 30 days ago | 60 days ago | 90 days ago | Change |
|---|---|---|---|---|---|---|
| Fiscal year ending Dec 31, 2026 | -$0.71 | -$0.74 | -$0.74 | -$0.75 | -$0.70 | N/A |
| Fiscal year ending Dec 31, 2027 | -$0.60 | -$0.59 | -$0.59 | -$0.57 | -$0.53 | N/A |
| Quarter ending Mar 31, 2027 | -$0.17 | -$0.15 | -$0.15 | -$0.15 | -$0.12 | N/A |
Frequently Asked Questions About MYGN
What is the MYGN stock forecast?
Consensus analyst estimates put Myriad Genetics's EPS at -$0.71 for the fiscal year ending Dec 31, 2026, on revenue of $785.10M. The consensus rating from 9 analysts is Hold.
How do analysts rate MYGN stock?
Of 9 analysts covering Myriad Genetics, 0 rate it Strong Buy, 1 Buy, 6 Hold, 1 Sell and 1 Strong Sell, for a consensus of Hold.
What EPS do analysts expect from MYGN next year?
For the fiscal year ending Dec 31, 2026, the consensus EPS estimate is -$0.71, with estimates from -$0.85 to -$0.66 from 6 analysts. For the fiscal year ending Dec 31, 2027, the consensus EPS estimate is -$0.60, with estimates from -$1.24 to -$0.28 from 7 analysts.
What revenue do analysts expect from Myriad Genetics next year?
For the fiscal year ending Dec 31, 2026, the consensus revenue estimate is $785.10M, with estimates from $778.40M to $787.90M. For the fiscal year ending Dec 31, 2027, the consensus revenue estimate is $737.70M, with estimates from $651.90M to $820.23M.
How many analysts cover MYGN?
9 analysts rate Myriad Genetics stock, and 6 analysts estimate its EPS for the fiscal year ending Dec 31, 2026.
MYGN pages: Overview, Earnings, Forecast, Financials, Valuation, Competitors, Government Contracts